Here, we reveal that SLC25A22, a mitochondrial glutamate carrier, is involved in maintaining an immune repressive microenvironment in KRAS-mutant CRC, and that targeting SLC25A22 could re-activate antitumor immunity and synergize with anti-PD1 to induce tumor regression. Here, KRAS is linked to neoplasm.